MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma

Lei Lei¹, Zhiming Jiang¹, Gu Zhang², Qiaoyuan Cheng³ and Hongyang Lu¹,4*

Abstract

Background: The response to temozolomide (TMZ) treatment in small-cell lung cancer (SCLC) correlated with O(6)-methylguanine -DNA methyltransferase (MGMT) promoter methylation. 1p/19q co-deletion within oligodendroglioma is a responsive predictor for TMZ. Currently, the status of MGMT promoter methylation and 1p/19q co-deletion in pulmonary carcinoid (PC) and large-cell neuroendocrine carcinoma (LCNEC) is not reported.

Methods: Nine PC [two atypical carcinoids (AC), seven typical carcinoids (TC)] and six LCNEC patients were collected retrospectively. The pyrosequencing and fluorescence in situ hybridization were used to detect the MGMT promoter methylation and 1p/19q co-deletion in surgically resected specimens. Kaplan–Meier analysis was used to assess the rate of disease-free survival (DFS).

Results: MGMT promoter methylation was found in two (2/6, 15.3%) LCNEC patients but not in any PC patients. Three (3/6, 50%) 1p and two (2/6, 33.3%) 19q single deletions were found in LCNEC patients. One 1p single deletion was found in AC patients. One (1/7, 14.3%) 1p and two (2/7, 28.6%) 19q single deletions were found in TC patients. After a median follow-up of 38 months, three LCNEC patients developed distant metastasis and one patient died of LCNEC disease. The DFS of PC patients was much longer than LCNEC patients ($\chi^2 = 7.565, P = 0.006$).

Conclusions: MGMT promoter methylation and 1p/19q co-deletion might not be the ideal biomarkers for TMZ treatment in TC/AC patients. Thus, the detection of MGMT promoter methylation and whether it can be used as a medication for TMZ in LCNEC patients necessitates investigation. Furthermore, 1p deletion could be a negative prognostic factor for LCNEC patients.

Keywords: Pulmonary carcinoid, Large-cell neuroendocrine carcinoma, MGMT methylation, 1p/19q co-deletion

Background

Patients with pulmonary carcinoid (PC) tumors and low grade (typical carcinoid (TC)) and intermediate grade (atypical carcinoid (AC)) neuroendocrine tumors accounted for 1% of the lung cancer patients undergoing surgical treatment [1, 2]. PC shows common driver mutations from non-small-cell lung cancer (NSCLC) [3]. Surgery is the primary mode of treatment for stage I, II, or IIIA patients with TC or AC [4]. For the progressive pulmonary carcinoid tumors, systemic therapy with a combination of etoposide and platinum was still commonly used albeit with limited effects [5]. However, temozolomide (TMZ) as monotherapy or combined with capecitabine has been shown to be effective and well-tolerated [5, 6]. The combination of TMZ/cisplatin/docetaxel showed a remarkable response in one heavy treated metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC) patient [7].

* Correspondence: luhy@zjcc.org.cn
¹Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (lung and esophagus), Zhejiang Cancer Hospital, No. 1 East Banshan Road, Gongshu District, Hangzhou 310022, People’s Republic of China
²Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, People’s Republic of China
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The response to TMZ treatment in small-cell lung cancer (SCLC) may be associated with O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation [8]. 1p/19q co-deletion is a positive response biomarker for TMZ treatment in oligodendrogliomas [9] and SCLC [10]. Unique profiles of aberrant methylation were observed in both SCLC and PC patients [11], and the potential PC patients who might benefit from TMZ are still to be ascertained [12]. However, whether MGMT promoter methylation or 1p/19q co-deletion existed in PC and LCNEC patients is yet unknown.

In order to elucidate the status of MGMT methylation and 1p/19q co-deletion in PC and LCNEC patients, two cases of AC, seven cases of TC, and six cases of LCNEC patients who underwent surgery were assimilated retrospectively and studied from the Zhejiang Cancer Hospital in China between 2008 and 2016.

Methods
Patients’ characteristics
Resected tumor samples were retrospectively collected from six LCNEC, seven TC, and two AC patients from the Zhejiang Cancer Hospital in China between 2008 and 2016. The pathological diagnosis was defined by the World Health Organization [13]. Patients were staged according to the eighth TNM classification for lung cancer [14]. Patient characteristics such as gender, age, the pathological type, stages, smoking history, and whether or not chemotherapy and/or radiotherapy was administered are described in Table 1. This study was approved by the Medical Ethics Committee of Zhejiang Cancer Hospital.

Detection of MGMT promoter methylation and 1p/19q co-deletion
The methylation analysis of MGMT promoter was performed on bisulfite-converted DNA that was performed using a commercially available kit [EpiTect Bisulfite Kit (48)]. Subsequently, the bisulfite-converted DNA was utilized in the PCR reaction mix. The PCR conditions were as follows: firstly, 37 °C for 3 min and 95 °C for 3 min; secondly, 14 cycles of 95 °C for 15 s and 65 °C for 45 s; and finally, 26 cycles of 95 °C for 15 s and 60 °C for 45 s. Three microliters of amplification product was evaluated on AGE (agarose gel electrophoresis); 10 μL PCR product was combined with DNA fixing mix and shocked for 10 min at 1400 rpm (room temperature). Complete primer dilution with annealing buffer during this time. Bind PCR products with primers using PyroMark Q24 Vacuum Workstation (001790). Then sequence by PyroMark Q24 MDX (QIAGEN, Biotage, USA). Finally, results will be statistically analyzed using PyroMark Q24 Software (CpG mode). The 1p/19q co-deletion was detected in as reported previously by Lu et al. [10].

Follow-up
The follow-up deadline was May 31, 2017. The median follow-up was 38 (11–112) months. Fourteen patients were alive, one LCNEC patient died, and no patients were lost to follow-up.

Statistical analysis
The disease-free survival (DFS) was defined as the time from diagnosis to the progression of the disease or death, whichever is earlier or the last visit date. Kaplan–Meier

| Patient | Age | Sex | pTNM stage | Tumor type | Smoking status | Ki-67 (%) | Therapy |
|---------|-----|-----|------------|------------|---------------|-----------|---------|
| 1       | 70  | M   | T2aN0M0,IB| LCNEC      | No            | 40        | S + C   |
| 2       | 57  | M   | T1cN0M1b,IV| LCNEC      | Yes           | 30        | S + C + R |
| 3       | 56  | F   | T2aN0M0,IB| LCNEC      | No            | 60        | S + C   |
| 4       | 58  | M   | T3N1M0,IIA| LCNEC      | Yes           | 70        | S + C + R |
| 5       | 62  | M   | T1aN2M0,IIIA| LCNEC      | Yes          | 60        | S + C   |
| 6       | 48  | F   | T3N2M0,IIA| LCNEC      | No           | –         | S + C + R |
| 7       | 44  | F   | T2aN0M0,IB| TC         | No           | –         | S       |
| 8       | 50  | M   | T1cN2M0,IIIA| AC        | No           | –         | S + C + R |
| 9       | 50  | F   | T2aN0M0,IB| AC         | No           | –         | S       |
| 10      | 41  | M   | T1bN0M0,IA2| TC        | No           | –         | S       |
| 11      | 61  | M   | T2bN0M0,IIA| TC        | Yes          | 1         | S       |
| 12      | 49  | M   | T1bN0M0,IA2| TC        | No           | 8         | S       |
| 13      | 63  | F   | T2bN1M0,IIA| TC        | No           | 5         | S       |
| 14      | 51  | F   | T1aN0M0,IIA| TC        | No           | 1         | S       |
| 15      | 53  | M   | T1bN0M0,IIA| TC        | No           | 2         | S       |

LCNEC large-cell neuroendocrine carcinoma, TC typical carcinoid, AC atypical carcinoid, S surgery, C postoperative chemotherapy, R postoperative radiotherapy
analysis was used to assess the DFS). The log-rank test was used to estimate and compare the rate of survival. All statistical analyses were carried out on an intention-to-treat basis using the SPSS 15.0 software package (SPSS Inc., Chicago, IL, USA).

**Results**

The median age was 50 (41–63) years for TC/AC and 58 (48–70) years for LCNEC patients. The majority of the patients presented a postoperative mass size of T1–2, regional lymph node metastasis of N0–1, and no adjuvant treatment after surgery except in one patient (T1cN2M0, stage IIIA) who had received 4 cycles of etoposide and platinum combination chemotherapy and local radiotherapy postoperatively. One pulmonary LCNEC patient with de novo IV stage underwent excision of brain metastatic lesion and chemotherapy with 2 cycles of etoposide with cisplatin and 2 cycles of docetaxel with cisplatin and the palliative pulmonary radiotherapy. All the other PC patients received no adjuvant chemotherapy or radiotherapy, while the pulmonary LCNEC patients received combined chemotherapy containing platinum regimen as adjuvant chemotherapy, and three patients also accepted the adjuvant radiotherapy. The de novo stage IV LCNEC patient progressed in the brain and lung only 1 year after the palliative cerebral metastatic tumor excision and systemic therapy. The other two LCNEC patients developed distant metastases (one case in cervical vertebrae, one case in brain), and only one patient with cervical vertebrae metastasis died. None of the TC/AC patients showed a relapse or metastasis after surgery during the median follow-up of 51 (11–112) months (Table 2). The DFS of PC patients was much better than that of LCNEC patients ($\chi^2 = 7.565$, $P = 0.006$) (excluding the patient of de novo stage IV LCNEC patient).

The MGMT promoter methylation was found in two (2/6, 15.3%) LCNEC patients (Fig. 1). Three (50%) 1p single deletion and two (33.3%) 19q single deletions were found in LCNEC patients (Fig. 1 and Additional file 1: Figure S1). 1p single deletion was found in one AC patient. Another one (1/7, 14.3%) 1p and two (2/7, 28.6%) 19q single deletions were found in TC patients. Three PC patients failed MGMT promoter methylation testing because of the quality of specimens. No MGMT promoter methylation was found in the remaining TC/AC patients. 1p/19q co-deletion was not found in all patients (Table 2).

**Discussion**

Dixon et al. reported that 75.5% of PCs were females, and the median age was 60.7 years, and 53.1% were smokers [15]. Ayadi-Kaddour et al. reported 56 men and 59 women with a mean age of 43.73 years in a cohort of 100 TC and 15 AC patients [4]. We found that 44.4% of PCs were females, TCs were more than ACs (77.8 vs. 22.2%), and only one male patient was a smoker (11.1%) in nine PCs with a median age of 50 (41–63) years. The clinical characteristics of patients in the current study were similar to those reported previously [4, 15]. The outcome of PC patients was favorable after surgery, and the factors affecting the survival included tumor size, nodal status, distant metastasis, and typical/atypical tumor [4, 16]. TCs have a better 5-year survival rate and lower incidence of metastasis than ACs after surgery [17]. Somatostatin

| Patient | 1p Del | 19q Del | MGMT Met | Metastasis (ML) | DFS (mon) | OS (mon) |
|---------|--------|---------|----------|----------------|-----------|----------|
| 1       | No     | Yes     | No       | Yes (TV)       | 10        | 36       |
| 2       | Yes    | No      | No       | Yes (B)        | 29        | 29       |
| 3       | No     | Yes     | Yes      | No             | 22        | 22       |
| 4       | No     | No      | No       | No             | 41        | 41       |
| 5       | Yes    | No      | Yes      | Yes (B)        | 12        | 44       |
| 6       | Yes    | No      | No       | Yes (CV; DOD)  | 9         | 34       |
| 7       | No     | No      | –        | No             | 112       | 112      |
| 8       | No     | No      | No       | No             | 112       | 112      |
| 9       | Yes    | No      | No       | No             | 101       | 101      |
| 10      | No     | Yes     | –        | No             | 84        | 84       |
| 11      | No     | No      | No       | No             | 37        | 37       |
| 12      | Yes    | No      | No       | No             | 31        | 31       |
| 13      | No     | No      | No       | No             | 51        | 51       |
| 14      | No     | No      | –        | No             | 38        | 38       |
| 15      | No     | Yes     | No       | No             | 11        | 11       |

LCNEC large-cell neuroendocrine carcinoma, Del deletion, Met methylation, ML metastatic lesions when the first metastasis occurred, B brain, TV thoracic vertebra, CV cervical vertebra, DOD dead of disease, DFS disease-free survival, OS overall survival
analogs are considered as the first-line treatment of carcinoid syndrome, especially in some low-grade TCs and ACs. Systemic chemotherapy is recommended for progressive and unresectable PCs. Compared to other palliative chemotherapies, TMZ has similar anti-tumor efficacy but is well-tolerated and could be used in metastatic brain PCs [5].

LCNEC was first introduced by Travis in 1991 and defined as a variant of large-cell carcinoma by the World Health Organization (WHO) from 1999 to 2004 [18–20]. When sufficient specimens are available for the diagnosis of LCNEC, surgical specimens should be the first choice than biopsy or cytology specimens [21]. LCNECs comprise of 1.6–3% resectable lung cancers [22, 23] that are common in males [24]. Reportedly, the 5-year overall survival varies between 13 and 57% for LCNECs [23–25]. In contrast to PCs, LCNECs are similar to SCLCs, always related with smoking history [26]. In the current study, the median age of six LCNECs was 58 (48–70) years, half of them were smokers, and two were female patients. The postoperative adjuvant chemotherapy regimen was a platinum-containing regimen consisting of two drugs of 4 cycles according to the recommendations of the NCCN guidelines. After the median follow-up of 35 (29–44) months, four out of six patients developed distant metastasis and one died due to the disease. Moreover, two had vertebral bone metastasis, while another two had brain metastasis. The median DFS was worse in LCNEC patients than in PC patients (12 vs. 51 months, \( P = 0.006 \)). No standard chemotherapy for advanced LCNEC is yet recommended. Compared to SCLC, LCNEC responded with inferior efficacy to first-line cisplatin and irinotecan chemotherapy as assessed by the response rate (RR) and median survival time (MST) (RR 46.7 vs. 80%, respectively, \( P = 0.0823 \); MST 12.6 vs. 17.3 months, respectively, \( P = 0.047 \)) [27]. The prognosis of LCNEC in neuroendocrine lung carcinoma seemed to occur between PC and SCLC and rather prone to the poor prognosis of SCLC.

Advanced lung cancer remains to be a catastrophic disease, partly due to the high incidence of brain metastasis [28]. TMZ is not much of a blood-brain barrier penetrating cytotoxic drug that is rather proven to be effective in malignant brain metastasis treatment [29, 30]. TMZ-based chemotherapy is recommended as first- or second-line treatment for TC or AC with negative somatostatin receptor (SSR) and rapid progression [31]. In our previous report, 33 SCLC specimens obtained from surgery were collected retrospectively and analyzed by high-resolution melting (HRM) analysis and methylation-specific polymerase chain reaction (MSP); MGMT promoter methylation was detected in 17 patients (51.5%) [32]. 1p/19q co-deletion was found in three patients, who survived after 58, 50, and 30 months of follow-up comprising of 32 SCLC resected specimens, thereby indicating a good prognostic factor in SCLC [10]. Several studies reported the use of TMZ in treating LCNEC patients [7]. Toyooka et al. demonstrated that bronchial carcinoids had lower frequencies of MGMT methylation than SCLC; however, the difference is not significant [11]. Three PC patients failed in MGMT promoter methylation testing owing to poor quality of specimens, and the remaining had negative results. Consequently, whether the frequency of MGMT promoter methylation is lower as compared to SCLC is yet to be elucidated. Currently, no study focusing on MGMT promoter methylation in LCNEC or 1p/19q deletion in both PC and LCNEC patients has been reported. Despite the small number of patients incapable of survival analysis, we deduced the following: firstly, MGMT promoter methylation was detected in two LCNEC but not TC/AC patients,

![Fig. 1](image_url)
which might be correlated to the better outcome of TC/AC than LCNEC patients. Secondly, three metastatic LCNEC patients carried the deletion of 1p, thereby designating it as an unfavorable prognostic factor for LCNEC patients.

Conclusions

Although the number of cases in this study was small, the specimens used for marker detection and pathological diagnosis originated from surgical specimens with reliable results. To the best of our knowledge, this is the first report about the exploratory detection of MGMT and chromosome 1p/19q deletion on three rare pulmonary neuroendocrine carcinomas in addition to SCLC. MGMT promoter methylation and 1p/19q co-deletion may not be an ideal biomarker for TMZ treatment in TC/AC patients. Furthermore, the MGMT promoter methylation could be used as medication instruction for TMZ in LCNEC patients. The deletion of 1p might be a negative prognostic factor for LCNEC, and a prolonged follow-up and large sample size would be valuable for further verification.

Additional file

Additional file 1: Figure S1. Positive control and negative control for 1p and 19q. 1p was 52% and 19q was 66% in positive control; 1p was 5% and 19q was 3% in negative control. (JPEG 188 kb)

Funding

This work was supported by the National Natural Science Foundation (No. 811303213), Zhejiang Province Medical Science Project of China (201502A006, 2015YB052), and 1022 Talent Training Program of Zhejiang Cancer Hospital.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

LL participated in the design of the study, collected the data, analyzed data, and drafted the manuscript. JZM participated in the design of the study and completed the experimental study. CQY participated in the design of the study and drafted the manuscript. ZG collected the data and completed the experimental study. FH participated in the design of the study, collected the data, analyzed data, and completed the experimental study. TMZ participated in the design of the study, collected the data, and analyzed data. LL participated in the design of the study, collected the data, and analyzed data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Medical Ethics Committee of Zhejiang Cancer Hospital. The specimens of this study were obtained from the Biological Sample Bank of Zhejiang Cancer Hospital, and the patients signed the written informed consents to preserve their specimens in the Biological Sample Bank of Zhejiang Cancer Hospital for use in the research. In this retrospective study, one patient died, and exempt written informed consent was approved by the Medical Ethics Committee of the Zhejiang Cancer Hospital.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (lung and esophagus), Zhejiang Cancer Hospital, No. 1 East Banshan Road, Gongxu District, Hangzhou 310022, People’s Republic of China. 2Department of Pathology, Zhejiang Cancer Hospital, Hangzhou 310022, People’s Republic of China. 3Department of Health Food and Cosmetics, Zhejiang Institute for Food and Drug Control, Hangzhou, People’s Republic of China. 4Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, People’s Republic of China.

Received: 2 November 2017 Accepted: 7 June 2018

Published online: 18 June 2018

References

1. Steuer CE, Behera M, Kim S, Chen Z, Saba NF, Pillai RN, et al. Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis. J Thorac Oncol. 2015;10(3):479–85.

2. Ichiki Y, Nagashima A, Yasuda M, Takenoyma M. Carcinoid tumors of the lung: a report of 11 cases. Asian J Surg. 2013;36(3):116–20.

3. Armengol G, Sarhadi VK, Rönty M, Tikkanen A, Knuittla A, Knuittla S. Driver gene mutations of non-small-cell lung cancer are rare in primary carcinoids of the lung: NGS study by ion Torrent. Lung. 2015;193(2):303–8.

4. Ayadi-Kaddour A, Marghli A, Zairi S, Zribi H, Ismail O, Braham E, et al. Bronchopulmonary carcinoid tumors: Tunisian experience with 115 surgically treated cases. Rev Pneumol Clin. 2015;71(6):319–26.

5. Caplin ME, Badin E, Faverola P, Filosso P, Garcia-Yuste M, Lim E, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604–20.

6. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13(10):2986–91.

7. Gounaris I, Rahamim J, Shivasanker S, Earl S, Lyons B, Yiannakis D. Marked response to a cisplatin/docetaxel/temozolomide combination in a heavily pretreated patient with metastatic large cell neuroendocrine lung carcinoma. Anti-Cancer Drugs. 2007;18(10):1227–30.

8. Pietanza MC, Kadota K, Huberman K, Sima CS, Fiore JJ, Sumner DK, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res. 2012;18(4):1138–45.

9. Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol. 2006;24(29):4746–53.

10. Lu H, Xu H, Xie F, Qin J, Han N, Fan Y, et al. 1p/19q codeletion and RET rearrangements in small-cell lung cancer. Onco Targets Ther. 2016;9:3571–7.

11. Toyoooka S, Toyoooka KD, Marumaya R, Virmani AK, Giraud L, Miyajima K, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther. 2001;1(1):61–7.

12. Vansteenkiste J. Pulmonary carcinoid: a rare thoracic malignancy, a high need for better defined systemic therapy. Ann Oncol. 2015;26(8):1527–9.

13. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–60.

14. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):339–51.

15. Duxon RK, Britt EJ, Netzer GA, Afshar M, Burke A, Liu S, et al. Ten-year single center experience of pulmonary carcinoid tumors and diagnostic yield of bronchoscopic biopsy. Lung. 2016;194(6):905–10.

16. Stanic J, Zatic B, Anjeljukovic A, Sarcev T, Eri Z, Boskovic T, et al. Clinical prognostic factors and outcome of surgical treatment in patients with early-stage bronchial carcinoid tumors. J BUON. 2009;15(3):524–8.

17. Kulke MH. Clinical presentation and management of carcinoid tumors. Hematol Oncol Clin North Am. 2007;21(3):433–55.

18. Travis WD, Lunnio RL, Tsokos MG, Hitchcock CL, Cutler GB Jr, Niman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell...
neuroendocrine carcinoma: an ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15(6):529-53.

19. Travis WD, Colby T, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumours. In: Springer Science & Business Media; 2012.

20. Travis WD, Harris C. Pathology and genetics of tumours of the lung, pleura, thymus and heart, vol. 2004. Feance: IARC Press; 2004.

21. Karahara N, Wakuda K, Omori S, Nakashima K, Ono A, Taira T, et al. Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma. Mol Clin Oncol. 2017;6(5):718–22.

22. Takai H, Asamura H, Maeshima A, Suzuki K, Kondo H, Niki T, et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg. 2002;124(2):285–92.

23. Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRα, PDGFRβ, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 2005;23(34):8774–85.

24. Travis WD. Lung tumours with neuroendocrine differentiation. Eur J Cancer. 2009;45(45 Supple 1):251–66.

25. Travis W. Advances in neuroendocrine lung tumors. Ann Oncol. 2010;21(suppl 7):vi65–71.

26. Swarts DR, Ramaekers FC, E-JM S. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta. 2012;1826(2):255–71.

27. Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M, et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. J Thorac Oncol. 2013;8(7):980–4.

28. Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdilawa A, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol. 2017;3(6):827–31.

29. Siegal T. Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas. Adv Tech Stand Neurosurg. 2016;43:91-108.

30. Zhao H, Wang S, Song C, Zha Y, Li L. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients’ survival: a meta-analysis. World J Surg Oncol. 2016;14(1):261.

31. Hilal T. Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management. Ther Adv Med Oncol. 2017;9(3):189–99.

32. Lu H, Qin J, Xu H, Han N, Xie F, Mao W. O6-methyl-guanine-DNA methyltransferase methylation and IDH1/2 mutation in small cell lung cancer. Exp Ther Med. 2017;14(1):398–402.